Biosimilar Denosumab Matches Reference on Lumbar Spine Bone Density
This meta-analysis gives geriatric pharmacists pooled randomized evidence that denosumab biosimilars are therapeutically interchangeable for postmenopausal osteoporosis, with a minor total hip signal favoring the reference product.
📅 Journal publication: Jul 29, 2026·Last updated: Aug 12, 2026
denosumabbiosimilar denosumabRANKL inhibitorpostmenopausal osteoporosisbone mineral densitymeta-analysisgeriatric pharmacyimmunogenicityGeriatrics / Geriatric Pharmacy
Biosimilar denosumab matches reference in treating osteoporosis.
Denosumab is used to manage osteoporosis in postmenopausal women, and understanding the efficacy of its biosimilar is crucial for safe, cost-effective treatment options. Both reference and biosimilar denosumab showed similar lumbar spine bone mineral density (BMD), though reference denosumab had a slight advantage in hip BMD. This study indicates biosimilar denosumab is a viable alternative to reference denosumab, but further studies are needed for long-term safety and efficacy in diverse populations. Biosimilar denosumab may be as effective as reference denosumab in postmenopausal osteoporosis.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Zainab S, Zaheer L, Sheikh AR, Khalid MS, Arshad MZ, Khatoon A, Zahra N, Ahmed E, Zakir E, Fatima E, Tariq A, Abbas K, Kanwal A, Haq UU, Khan AA, Suman S
Citation:Zainab S, Zaheer L, Sheikh AR, et al. Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2026. doi:10.1007/s00198-026-08159-3